# A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)

> **NCT02924766** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 34 (actual)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** Niraparib
- **DRUG:** Apalutamide
- **DRUG:** Abiraterone Acetate
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT02924766
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-03
- **Primary completion:** 2019-07-18
- **Final completion:** 2019-07-19
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2020-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02924766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02924766, "A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02924766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*